Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

David Borun headshot

Should You Buy the Dip in CRISPR Therapeutics?

A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?

    Vertex Pharmaceuticals (VRTX) Down 1.2% Since Earnings Report: Can It Rebound?

    Vertex Pharmaceuticals (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      David Borun headshot

      Is Genome Editing the Next Biotech Breakthrough?

      CRISPR technology is promising to be the foundation the treatment of 1000s of diseases

        The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex

        The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex

          Mark Vickery headshot

          Top Research Reports for General Dynamics, Enbridge & CSX Corporation

          Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), Enbridge (ENB) and CSX Corporation (CSX).

            Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

            The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

              Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales

              Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.

                Is a Beat in Store for Vertex (VRTX) This Earnings Season?

                Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.

                  Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)

                  Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

                    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

                      Indrajit Bandyopadhyay headshot

                      Pharma M&A Active This Week: 4 Potential Buyout Targets

                      Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

                        Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now?

                        Smart Beta ETF report for PBE

                          Mark Vickery headshot

                          Top Research Reports for Oracle, Vale & General Mills

                          Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Vale (VALE) and General Mills (GIS).

                            3 Biotech Stocks With Rising Earnings Estimates Post Q4

                            The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.

                              Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo

                              The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.

                                The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex

                                The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex

                                  Mark Vickery headshot

                                  Top Analyst Report for Amgen, TOTAL S.A. & Marriott

                                  Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), TOTAL S.A. (TOT) and Marriott (MAR).

                                    Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

                                    Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.

                                      The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services

                                      The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services

                                        REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?

                                        Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.

                                          Mark Vickery headshot

                                          Top Stock Reports for Wells Fargo, Caterpillar & Schlumberger

                                          Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Caterpillar (CAT) and Schlumberger (SLB).

                                            The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                                            The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

                                              Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

                                              Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

                                                While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.

                                                  Arpita Dutt headshot

                                                  Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February

                                                  Here is a look at Vertex (VRTX) and a few other companies that await a decision from the FDA in February for label expansions or new drugs.